Investigational Drug Information for Plinabulin
✉ Email this page to a colleague
What is the development status for investigational drug Plinabulin?
Plinabulin is an investigational drug.
There have been 12 clinical trials for Plinabulin.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 29th 2018.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Neutropenia. The leading clinical trial sponsors are BeyondSpring Pharmaceuticals Inc., Memorial Sloan Kettering Cancer Center, and Merck Sharp & Dohme LLC.
There are thirty US patents protecting this investigational drug and two hundred and fifty-four international patents.
Summary for Plinabulin
| US Patents | 30 |
| International Patents | 254 |
| US Patent Applications | 125 |
| WIPO Patent Applications | 77 |
| Japanese Patent Applications | 15 |
| Clinical Trial Progress | Phase 3 (2018-05-29) |
| Vendors | 34 |
Recent Clinical Trials for Plinabulin
| Title | Sponsor | Phase |
|---|---|---|
| First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC | Xiaorong Dong | Phase 2 |
| Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) | BeyondSpring Pharmaceuticals Inc. | Phase 2 |
| Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) | Merck Sharp & Dohme LLC | Phase 2 |
Clinical Trial Summary for Plinabulin
Top disease conditions for Plinabulin
Top clinical trial sponsors for Plinabulin
US Patents for Plinabulin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Plinabulin | ⤷ Subscribe | Method of treating a brain tumor | BeyondSpring Pharmaceuticals, Inc. (New York, NY) | ⤷ Subscribe |
| Plinabulin | ⤷ Subscribe | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Subscribe |
| Plinabulin | ⤷ Subscribe | Nanoparticle formulations for delivering multiple therapeutic agents | AMRITA VISHWA VIDYAPEETHAM (Kochi, Kerala, unknown) | ⤷ Subscribe |
| Plinabulin | ⤷ Subscribe | Plinabulin compositions | BeyondSpring Pharmaceuticals, Inc. (New York, NY) | ⤷ Subscribe |
| Plinabulin | ⤷ Subscribe | Method of treating cancer associated with a RAS mutation | BeyondSpring Pharmaceuticals, Inc. (New York, NY) | ⤷ Subscribe |
| Plinabulin | ⤷ Subscribe | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | Duquesne University of the Holy Spirit (Pittsburgh, PA) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Plinabulin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Plinabulin | Australia | AU2016229295 | 2035-03-06 | ⤷ Subscribe |
| Plinabulin | Australia | AU2021254549 | 2035-03-06 | ⤷ Subscribe |
| Plinabulin | Brazil | BR112017018964 | 2035-03-06 | ⤷ Subscribe |
| Plinabulin | Canada | CA2978679 | 2035-03-06 | ⤷ Subscribe |
| Plinabulin | Chile | CL2017002242 | 2035-03-06 | ⤷ Subscribe |
| Plinabulin | China | CN107530340 | 2035-03-06 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
